Akari Share Price

Akari Share Price

NASDAQ: AKTX | Mega Cap | Healthcare
$7.17
+$7.17 (--%) Last updated on 19 Nov, 2026 | 01:00 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Akari Stock Performance

Open
$5.72
Prev. Close
N/A
Circuit Range
N/A
Day Range
$5.72 - $7.17
Year Range
$0.12 - $24.99
Volume
300
Average Traded
$6.20

Akari Share Price Chart

Line chart of the Akari price trend over the selected period. The price rose overall, ranging from 5.72 to 7.17, ending at 7.17.
$5.72$7.17
L
Show Current Price
H

Akari Stock Fundamentals & Key Indicators

Market Cap
$482.74B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-12.87
Revenue (TTM)
$0.00
Return On Equity (TTM)
-168.00%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
8.68%

Akari Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$5.30-$14.46-$4.81-$4.84
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-172.83%66.74%-0.62%

Akari Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$17.75-$10.01-$19.79-$17.30
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A43.61%-97.70%12.58%

Akari Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets42.4347.610.010.02
Current Assets5.462.954.3413.82
Total Assets47.8950.564.3613.83
Non Current Liabilities7.218.420.00.0
Current Liabilities12.3519.914.5812.04
Total Liabilities19.5628.334.5812.04
Shareholders' Equity28.3322.23-0.231.79

Akari Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-10.57-12.55-16.43-21.5
Investing0.00.380.00.0
Financing13.1710.997.0225.29

Corporate Actions

Split
Ex-date: 31 Mar 2026

Split
Ex-date: 17 Aug 2023

About Akari

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Akari Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$8.18
$7.17
-13.20%
Oct 2026
$9.64
$8.26
-14.85%
Sep 2026
$10.31
$9.70
+8.14%
Aug 2026
$7.54
$8.97
+11.58%
Jul 2026
$10.64
$8.04
-19.77%
Jun 2026
$15.76
$10.02
-38.15%
May 2026
$5.50
$16.20
+199.45%
Apr 2026
$5.46
$5.41
+4,334.43%
Mar 2026
$0.23
$0.12
-48.52%
Feb 2026
$0.24
$0.24
-5.95%
Jan 2026
$0.28
$0.25
-11.58%
Dec 2025
$0.45
$0.28
-38.18%

Akari Share Price FAQs